tradingkey.logo

InspireMD Inc

NSPR
1.990USD
-0.010-0.50%
收盘 12/19, 16:00美东报价延迟15分钟
83.42M总市值
亏损市盈率 TTM

InspireMD Inc

1.990
-0.010-0.50%

关于 InspireMD Inc 公司

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

InspireMD Inc简介

公司代码NSPR
公司名称InspireMD Inc
上市日期Apr 12, 2013
CEOSlosman (Marvin L)
员工数量85
证券类型Ordinary Share
年结日Apr 12
公司地址6303 Waterford District Drive
城市MIAMI
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编33126
电话18887766804
网址https://www.inspiremd.com/en/
公司代码NSPR
上市日期Apr 12, 2013
CEOSlosman (Marvin L)

InspireMD Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Andrea Tommasoli
Mr. Andrea Tommasoli
Chief Operating Officer
Chief Operating Officer
727.69K
--
Dr. Gary S. Roubin, M.D., Ph.D.
Dr. Gary S. Roubin, M.D., Ph.D.
Independent Director
Independent Director
656.42K
+7.89%
Ms. Kathryn Arnold
Ms. Kathryn Arnold
Independent Director
Independent Director
247.53K
--
Mr. Michael Berman
Mr. Michael Berman
Independent Director
Independent Director
189.12K
+17.93%
Mr. Danny L. (Dan) Dearen
Mr. Danny L. (Dan) Dearen
Independent Director
Independent Director
58.02K
--
Mr. Scott R. Ward
Mr. Scott R. Ward
Director
Director
--
--
Mr. Marvin L. Slosman
Mr. Marvin L. Slosman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul S. Stuka
Mr. Paul S. Stuka
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Amir Kohen
Mr. Amir Kohen
Vice President - Finance, Human Resources
Vice President - Finance, Human Resources
--
--
Mr. Shane Gleason
Mr. Shane Gleason
Vice President - Global Marketing, General Manager, North America
Vice President - Global Marketing, General Manager, North America
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Andrea Tommasoli
Mr. Andrea Tommasoli
Chief Operating Officer
Chief Operating Officer
727.69K
--
Dr. Gary S. Roubin, M.D., Ph.D.
Dr. Gary S. Roubin, M.D., Ph.D.
Independent Director
Independent Director
656.42K
+7.89%
Ms. Kathryn Arnold
Ms. Kathryn Arnold
Independent Director
Independent Director
247.53K
--
Mr. Michael Berman
Mr. Michael Berman
Independent Director
Independent Director
189.12K
+17.93%
Mr. Danny L. (Dan) Dearen
Mr. Danny L. (Dan) Dearen
Independent Director
Independent Director
58.02K
--
Mr. Scott R. Ward
Mr. Scott R. Ward
Director
Director
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
OTHER
845.00K
47.53%
Germany
360.00K
20.25%
Italy
324.00K
18.22%
Poland
249.00K
14.00%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Rosalind Advisors, Inc.
9.22%
Nantahala Capital Management, LLC
7.97%
abrdn Inc.
5.86%
Parkman Healthcare Partners LLC
5.76%
Velan Capital Investment Management LP
5.06%
其他
66.14%
持股股东
持股股东
占比
Rosalind Advisors, Inc.
9.22%
Nantahala Capital Management, LLC
7.97%
abrdn Inc.
5.86%
Parkman Healthcare Partners LLC
5.76%
Velan Capital Investment Management LP
5.06%
其他
66.14%
股东类型
持股股东
占比
Hedge Fund
30.30%
Individual Investor
17.01%
Investment Advisor/Hedge Fund
16.01%
Private Equity
5.04%
Investment Advisor
2.29%
Research Firm
0.01%
其他
29.34%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
59
17.22M
41.08%
+3.94M
2025Q2
66
22.15M
54.76%
+3.53M
2025Q1
62
18.33M
62.97%
+674.68K
2024Q4
58
17.14M
67.20%
+1.37M
2024Q3
54
16.79M
66.53%
-282.36K
2024Q2
54
16.34M
65.74%
-743.64K
2024Q1
54
14.90M
65.10%
+1.03M
2023Q4
56
13.53M
62.30%
-2.07K
2023Q3
52
13.61M
63.81%
+964.66K
2023Q2
52
12.52M
59.93%
+9.01M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Rosalind Advisors, Inc.
3.91M
9.36%
+1.62M
+70.62%
Aug 04, 2025
Nantahala Capital Management, LLC
2.32M
5.56%
--
--
Jun 30, 2025
Parkman Healthcare Partners LLC
1.24M
2.96%
+63.89K
+5.45%
Jun 30, 2025
Velan Capital Investment Management LP
2.14M
5.14%
+1.24M
+137.13%
Jul 30, 2025
OrbiMed Advisors, LLC
2.13M
5.11%
--
--
Jun 30, 2025
Marshall Wace LLP
1.86M
4.46%
--
--
Jun 30, 2025
Soleus Capital Management, L.P.
1.89M
4.52%
+940.83K
+99.52%
Jun 30, 2025
Slosman Marvin
1.14M
2.73%
+10.33K
+0.92%
Jul 30, 2025
Shore (Craig)
3.40M
8.15%
+2.29M
+205.73%
Apr 15, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
占比0.01%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1
公告日期
类型
比率
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1

常见问题

InspireMD Inc的前五大股东是谁?

InspireMD Inc 的前五大股东如下:
Rosalind Advisors, Inc.持有股份:3.91M,占总股份比例:9.36%。
Nantahala Capital Management, LLC持有股份:2.32M,占总股份比例:5.56%。
Parkman Healthcare Partners LLC持有股份:1.24M,占总股份比例:2.96%。
Velan Capital Investment Management LP持有股份:2.14M,占总股份比例:5.14%。
OrbiMed Advisors, LLC持有股份:2.13M,占总股份比例:5.11%。

InspireMD Inc的前三大股东类型是什么?

InspireMD Inc 的前三大股东类型分别是:
Rosalind Advisors, Inc.
Nantahala Capital Management, LLC
abrdn Inc.

有多少机构持有InspireMD Inc(NSPR)的股份?

截至2025Q3,共有59家机构持有InspireMD Inc的股份,合计持有的股份价值约为17.22M,占公司总股份的41.08%。与2025Q2相比,机构持股有所增加,增幅为-13.68%。

哪个业务部门对InspireMD Inc的收入贡献最大?

在FY2025Q2,--业务部门对InspireMD Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI